Latest filing published 02 Jan 2020 for ZEVRA THERAPEUTICS, INC., €3,481.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 12 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +59.3%Entry US$6.56 · Close at T+365 US$10.45
- -22.2%Entry US$14.80 · Close at T+365 US$11.52
- -73.5%Entry US$39.92 · Close at T+365 US$10.56
- +72.7%Entry US$44.00 · Close at T+365 US$76.00
- -51.6%Entry US$199.20 · Close at T+365 US$96.32
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Gordon K. Johnson: trading record in brief
Gordon K. Johnson discloses dealings in Zevra Therapeutics, Inc. to SEC (Form 4). In total, 12 filings cover trades dated from 21 April 2015 to 31 December 2019.
Purchases make up the whole of the open-market record (12 purchases, €53k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2020, the count stands at 2 purchases and no sales.
Half of the purchases are above €2,882 and half below. Of 11 purchases, 11 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 12 purchases with a full 90-day history, the hit rate stands at 58% and the median 90-day move at +5.4%. They describe history only and say nothing certain about the share price ahead.
On 2 January 2020 came the latest disclosure, an open-market purchase for €3,467 in Zevra Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Gordon K. Johnson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 shares@ US$0.3914.9% of flowCommon StockSEC:0001437749-20-000071:0Canonical exit: 30 Mar 2020 (T+90)
- 10,000 shares@ US$0.388414.8% of flowCommon StockSEC:0001437749-20-000071:1Canonical exit: 30 Mar 2020 (T+90)
- 2,000 shares@ US$0.81656.3% of flowCommon StockSEC:0001437749-19-018071:0Canonical exit: 8 Dec 2019 (T+90)
- 3,000 shares@ US$0.80329.3% of flowCommon StockSEC:0001437749-19-018071:1Canonical exit: 8 Dec 2019 (T+90)
- 5,000 shares@ US$0.825116.0% of flowCommon StockSEC:0001437749-19-018071:2Canonical exit: 8 Dec 2019 (T+90)
- 2,000 shares@ US$2.6019.3% of flowCommon StockSEC:0001437749-18-018242:0Canonical exit: 8 Jan 2019 (T+90)
- 1,000 shares@ US$2.659.8% of flowCommon StockSEC:0001437749-18-018242:1Canonical exit: 8 Jan 2019 (T+90)
- 1,000 shares@ US$2.619.6% of flowCommon StockSEC:0001437749-18-018242:2Canonical exit: 10 Jan 2019 (T+90)
- 1,000 shares@ US$2.556.7% of flowCommon StockSEC:0001437749-17-015334:0Canonical exit: 22 Nov 2017 (T+90)
- 2,000 shares@ US$2.6113.7% of flowCommon StockSEC:0001437749-17-015334:1Canonical exit: 22 Nov 2017 (T+90)
- 1,000 shares@ US$2.636.9% of flowCommon StockSEC:0001437749-17-015334:2Canonical exit: 22 Nov 2017 (T+90)
- 2,000 shares@ US$11.00Common StockSEC:0001209191-15-041656:0Canonical exit: 20 Jul 2015 (T+90)
12 of 12 declarations